Key result
Elevated lipoprotein(a) is a significant, genetically determined risk factor for premature cardiovascular disease that requires increased awareness and proactive screening.
Why the study?
High Lp(a) levels are an independent cardiovascular risk factor but are not usually measured due to low awareness.
Answers are grounded in this paper and cite their sources.
Elevated Lp(a) is an under-recognized, genetically determined cardiovascular risk factor, highlighting the need for increased screening and awareness.
This article presents three points of view on lipoprotein(a) [Lp(a)]: that of a patient, his endocrinologist, and a patient association, the Association Nationale des Hypercholestérolémies familiales et Lipoprotéines (a) (ANHET). By sharing his story, the patient reveals the severe impact his high Lp(a) levels had on his health, his daily life, and his family. The endocrinologist explains what Lp(a) is and its role as a risk factor for cardiovascular disease. As an expert in the field, he reviews the recommendations for the screening and management of Lp(a). The vice-president of ANHET describes the association’s fight to increase awareness of this risk factor among patients, the medical profession, and even politicians, and to bring about changes in the healthcare system. Given the large number of people concerned, the perspectives of the patient, the physician, and the patient association converge in raising awareness of the negative impact of high levels of Lp(a) on health and the importance of intensifying Lp(a) screening. See the Supplementary Material for a French-language version of this abstract. Lipoprotein(a), also known as Lp(a), is a lipoprotein that transports cholesterol in the blood. Levels of Lp(a) are genetically determined and vary considerably between people. High Lp(a) levels are a causative, independent risk factor for premature cardiovascular disease, stroke and calcific aortic stenosis, but are not usually measured by doctors, because there is low awareness of the risk Lp(a) poses. This article presents three points of view on Lp(a): that of a patient, his endocrinologist, and a patient association, the Association Nationale des Hypercholestérolémies familiales et Lipoprotéines (a) (ANHET). Unlike most types of lipoproteins/cholesterol, Lp(a) levels are not influenced by lifestyle. The patient in this article was lean, exercised regularly, and had a healthy diet, yet he had a heart attack before 40 years of age, and has had two more since, because of very high Lp(a) levels. The physician describes what Lp(a) is, how it is treated currently, and what the future holds. The only available treatment now is lipoprotein apheresis, which involves removing Lp(a) by pumping blood through a “purifying” machine, which is expensive, time-consuming, and inconvenient. Promising new treatments for reducing Lp(a) levels are being investigated in clinical trials, and the first of these treatments (pelacarsen) is likely to be available within a few years. The vice-president of ANHET describes the association’s role in supporting patients, educating physicians, and driving awareness at a government and policy level to improve rates of testing and screening, and improve access to effective treatment.
No takes yet. Share an insight, caveat, or question.
Favereaux et al. (2025) studied Elevated Lipoprotein(a) and Cardiovascular Disease. Elevated Lipoprotein(a) was evaluated. Elevated lipoprotein(a) is a significant, genetically determined risk factor for premature cardiovascular disease that requires increased awareness and proactive screening.
Synapse has enriched 10 related papers. Consider them for comparative context: